Geron said it might be able to resume early-stage trials of a stem cell treatment for complete thoracic spinal cord injury by the third quarter of 2010 under an agreement with the FDA. The agency had placed the studies on clinical hold after the treatment caused cysts in some animal subjects.

Related Summaries